The Relief Therapeutics (OTCMKTS:RLFTF) stock was on the move yesterday after its collaboration partner NRx Pharmaceuticals announced positive results for its COVID 19 treatment Zyesami.
It is a major development for Relief and it was no wonder that the stock soared by as much as 6% after the announcement yesterday. It was announced that Zyesami displayed efficacy and helped in the recovery of patients who had been critically ill from COVID 19 infection. Compared to placebo, more patients actually recovered after being treated with Zyesami.
However, that is not all. The product also displayed an important advantage over other treatments and helped in shortening the hospital stays of patients as well. Relief made a filing on the basis of the data that had been requested by the United States Food and Drug Administration. That being said, investors also need to keep in mind that the entirety of the results is going to be published in a peer-reviewed journal soon.